Sermorelin vs Ipamorelin: GHRH Analog vs Ghrelin-Receptor Secretagogue

The short version

Sermorelin vs ipamorelin is a comparison of two growth-hormone secretagogues that push the same gland through two different buttons. Sermorelin is a GHRH analog: it copies growth hormone-releasing hormone and presses the GHRH receptor. Ipamorelin belongs to a separate class — the GHRPs (growth hormone-releasing peptides) — and presses the ghrelin receptor instead (the same receptor the hunger hormone ghrelin uses). Because they act on different receptors, researchers often study them as complementary rather than as substitutes. Both prompt the pituitary to release the body's own growth hormone; both are prohibited in sport. This page is a mechanism comparison, not a usage guide.

Different receptor, different class

The defining difference is the receptor. Sermorelin acts on the GHRH receptor (GHRH-R), a class B G-protein-coupled receptor on pituitary somatotrophs, raising cAMP through the Gs/adenylate cyclase/PKA pathway to drive pulsatile growth-hormone release ^[12]. Ipamorelin acts on the ghrelin/growth-hormone-secretagogue (GHS) receptor — a different docking site entirely, the one the stomach hormone ghrelin normally uses.

That puts them in two classes. Sermorelin is a GHRH analog; ipamorelin is a GHRP-class secretagogue (the family that includes GHRP-6). The 2025 Nature Reviews Endocrinology review situates GHRH analogs within the broader landscape of growth-hormone secretory control ^[12], where GHRH-receptor agonists and ghrelin-receptor agonists are recognized as distinct, parallel inputs to the same somatotrophs.

Why the two mechanisms are studied together

Because GHRH-receptor and ghrelin-receptor stimulation converge on the same growth-hormone-producing cell by separate pathways, the two are often described as complementary: each input drives release through its own signaling, and the classes are studied side by side rather than as direct rivals. The GHRP class also carries its own distinct findings — the GH secretagogues ipamorelin and GHRP-6 increased bone mineral content in adult female rats, an effect attributed to the GHRP/secretagogue class ^[10].

That bone-mineral result is class-specific GHRP data, not a sermorelin finding — the same attribution discipline this digest applies to tesamorelin's body-composition data. Sermorelin's own evidence stays on the GH/IGF-1 axis: restored growth hormone and IGF-1 in older men ^[2], accelerated height velocity in children ^[1].

Sermorelin vs ipamorelin: what is the difference?

Sermorelin vs ipamorelin: what is the difference?

Sermorelin is a GHRH analog acting on the GHRH receptor; ipamorelin is a GHRP-class secretagogue acting on the ghrelin/GHS receptor ^[12]. They use different mechanisms and are often studied as complementary rather than interchangeable. Both prompt the pituitary to release endogenous growth hormone, and both are prohibited in sport.

Shared status, separate evidence

Sermorelin and ipamorelin share a regulatory and anti-doping context even though their mechanisms differ. Growth-hormone secretagogues as a group — GHRH analogs and GHRPs alike — appear on the WADA Prohibited List under hormone and metabolic modulators (S2) and are prohibited in sport at all times.

Their compounding status is not identical and should not be conflated: sermorelin is treated as a long-standing Category 1 bulk drug substance under FDA's interim 503A policy ^[15], whereas other GH-axis peptides — ipamorelin among them — were reviewed separately by the Pharmacy Compounding Advisory Committee in October 2024. The honest comparison keeps the evidence separate too: sermorelin's GH/IGF-1 human data ^[1][2] and ipamorelin's class-specific GHRP findings ^[10] are different bodies of research, not one shared record.